Matrix metalloproteinases generate angiostatin: effects on neovascularization

LA Cornelius, LC Nehring, E Harding… - The Journal of …, 1998 - journals.aai.org
LA Cornelius, LC Nehring, E Harding, M Bolanowski, HG Welgus, DK Kobayashi, RA Pierce…
The Journal of Immunology, 1998journals.aai.org
Angiostatin, a cleavage product of plasminogen, has been shown to inhibit endothelial cell
proliferation and metastatic tumor cell growth. Recently, the production of angiostatin has
been correlated with tumor-associated macrophage production of elastolytic
metalloproteinases in a murine model of Lewis lung cell carcinoma. In this report we
demonstrate that purified murine and human matrix metalloproteinases generate
biologically functional angiostatin from plasminogen. Macrophage elastase (MMP-12 or …
Abstract
Angiostatin, a cleavage product of plasminogen, has been shown to inhibit endothelial cell proliferation and metastatic tumor cell growth. Recently, the production of angiostatin has been correlated with tumor-associated macrophage production of elastolytic metalloproteinases in a murine model of Lewis lung cell carcinoma. In this report we demonstrate that purified murine and human matrix metalloproteinases generate biologically functional angiostatin from plasminogen. Macrophage elastase (MMP-12 or MME) proved to be the most efficient angiostatin-producing MMP. MME was followed by gelatinases and then the stomelysins in catalytic efficiency; interstitial collagenases had little capacity to generate angiostatin. Both recombinant angiostatin and angiostatin generated from recombinant MME-treated plasminogen inhibited human microvascular endothelial cell proliferation and differentiation in vitro. Finally, employing macrophages isolated from MME-deficient mice and their wild-type littermates, we demonstrate that MME is required for the generation of angiostatin that inhibits the proliferation of human microvascular endothelial cells.
journals.aai.org